News
AbbVie's CLL drug Venclyxto too expensive for NHS, says NICE
NICE has said AbbVie’s Venclyxto (venetoclax), in combination with development partner Roche's MabThera/Rituxan (rituximab), is not a cost-effective use of NHS resources as a treatment for
